• Explore /
  • Poster
  • / Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).

Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).

Abstract Poster

Authors

null

Masa Lasica

St. Vincent's Hospital Melbourne, Melbourne, VIC, Australia

Masa Lasica , Sikander Ailawadhi , Chengcheng Fu , Sheeba K. Thomas , Depei Wu , Shuhua Yi , Tanya Siddiqi , Qingsong Yin , John N. Allan , Wenming Chen , Jeffrey V Matous , Ru Feng , Zi Chen , Min Yu , Mingyu Li , Zicong He , Mohammad Ahmad , Hengbang Wang , Asher Alban Akmal Chanan-Khan , Yifan Zhai

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT04260217

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 7078)

DOI

10.1200/JCO.2024.42.16_suppl.7078

Abstract #

7078

Poster Bd #

61

Abstract Disclosures

Similar Posters

First Author: Sikander Ailawadhi

First Author: Jianyong Li

First Author: Elise A. Chong

First Author: Chunmei Bai